The federal contract IDV award, valued at up to $890,640.00, was issued by the Department of Veterans Affairs' (VA) Veterans Integrated Service Network 16 (VISN 16) to Veracyte, Inc., a for-profit provider of genomic testing services. The single-award IDV, awarded on October 1, 2024 with a potential completion date of September 30, 2029, will enable VISN 16 to efficiently access Veracyte's commercial laboratory capabilities for specialized pathology testing to support VA hospitals and clinics throughout the agency's northern and central California region.
The initial sources sought announcement indicates the VA is seeking vendors capable of providing the Afirma Genomic Sequencing Classifier, a genetic test used to determine if a thyroid has a malignancy for veterans who are poor candidates for surgery due to multiple comorbidities. The contract aims to procure these genomic classifier laboratory testing services to aid in clinical diagnosis and treatment planning for veterans served by VISN 16 facilities. Task orders issued under the IDV will cover the specialized pathology testing, with Veracyte delivering the services from its own laboratories on a firm fixed price basis.
Generated 9/18/24, 9:06 AM